Against All Odds: Advancing From R&D To Phase 3

By Sanjeev Luther

To pave a path in a field that is bound to be riddled with disappointments, uncertainties, and sometimes even utter failure, would deter most people from creating a career in biopharma. Harrowing statistics illustrate the hardships in successfully bringing a drug to market. In fact, over 90% of compounds never even enter Phase 1 clinical trials — a number that has not changed in decades. Advancing a pharmaceutical company is an uphill battle, with many challenges along the way from data analysis to FDA regulations to trial operations and beyond.